Analyst Reco. Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Real-time Estimate Cboe BZX Other stock markets 11:07:24 2024-06-10 am EDT			5-day change	1st Jan Change
121.9 ^USD	-1.19%		-1.72%	+26.61%

Jun. 03	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 1000	CI
Jun. 03	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to S&P 400 - Biotechnology	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sarepta Therapeutics Shares Fall After RBC Downgrade	May. 28	MT
RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Lowers Price Target to $142 From $157	May. 28	MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating	May. 17	MT
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	May. 14	MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating	May. 02	MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating	May. 02	MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating	Mar. 01	MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating	Feb. 29	MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating	Feb. 29	MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating	Feb. 29	MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $145 From $130, Keeps Buy Rating	Feb. 14	MT
BMO Capital Starts Sarepta Therapeutics With Outperform Rating, $170 Price Target	Jan. 31	MT
RBC Trims Price Target on Sarepta Therapeutics to $151 From $155, Keeps Outperform Rating	Jan. 25	MT
Needham Raises Price Target on Sarepta Therapeutics to $140 From $93, Keeps Buy Rating	Jan. 10	MT
RBC Raises Price Target on Sarepta Therapeutics to $155 From $148, Keeps Outperform Rating	Jan. 03	MT
Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Buy Rating, $109 Price Target	Dec. 12	MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors	Nov. 21	MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors	Nov. 21	MT
Needham Raises Price Target on Sarepta Therapeutics to $93 From $82, Keeps Buy Rating	Nov. 02	MT
Cantor Fitzgerald Downgrades Sarepta Therapeutics to Neutral From Overweight, Cuts Price Target to $40 From $166	23-10-31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Analyst Reco.

Filters